<p>低买高卖。这一直是投资者长期以来的良好策略。然而，考虑到 <strong>标准普尔 500 指数</strong> 接近历史最高点，按照这种方法找到值得购买的优质股票可能看起来很困难。</p>
<p>好消息是，这样做比你想象的要容易。以下是三只接近 52 周低点的优秀股票。</p>
<h2>1. D.R. Horton</h2>
<p><strong>D.R. Horton</strong>(DHI 0.95%)，美国最大的住宅建筑商，在过去 12 个月里让投资者经历了一场过山车般的旅程。不过，最近的旅程并不愉快，股票价格比 9 月份的峰值下跌了超过 30%，仅略高于其 52 周低点。</p>
<p>D.R. Horton 面临的主要问题可以用两个词来概括：抵押贷款利率。尽管美联储去年底降低了基准利率，但抵押贷款利率依然顽固地高企。当抵押贷款利率高时，越来越少的美国人能够负担得起购买新房。</p>
<p>抵押贷款利率会很快下降吗？我不知道。不过我知道的是，美国房地产市场的长期前景依然强劲——这对 D.R. Horton 在未来十年是个好兆头。</p>
<p>我还知道 D.R. Horton 的估值很有吸引力。其股票的预期前瞻性市盈率仅为 9.9 倍。即使是关于抵押贷款利率的积极消息也可能为这只被打压的股票提供一个良好的催化剂。</p>
<h2>2. Pfizer</h2>
<p><strong>Pfizer</strong>(PFE -0.43%) 的股票自 2021 年底以来一直处于普遍下滑的轨道。这一时机与全球接近走出 COVID-19 疫情的时刻不谋而合。随着 Pfizer 的 COVID-19 疫苗和抗病毒药物销售下滑，其股价也随之下跌。这只大型制药公司的股票现在接近过去 52 周的最低水平。</p>
<p>当然，Pfizer 仍面临一些挑战。特别是，未来几年内其几款产品将失去专利独占权，其中包括重磅药物 Eliquis、Ibrance 和 Xtandi。COVID-19 疫苗销售回到接近峰值水平的机会也微乎其微。</p>
<p>然而，Pfizer 相信它将在本十年的下半年实现稳健增长。怎么做到的？该公司的产品线中有一些新兴明星，如偏头痛治疗药物 Nurtec ODT 和癌症药物 Padcev、Adcetris 和 Tukysa。Pfizer 的研发管线中还有 115 个候选药物，其中五个正在等待监管批准，32 个处于后期临床测试阶段。</p>
<p>与此同时，Pfizer 的股票便宜，前瞻性市盈率仅为 8.7 倍。这家制药公司还支付股息，目前股价的前瞻性收益率超过 6.7%。</p>
<h2>3. 联合包裹</h2>
<p><strong>联合包裹</strong>(UPS 0.50%) 的股票在过去 12 个月中暴跌了约 20%。尽管最近几天小幅反弹，但该股票仍然接近其 52 周低点。</p>
<p>许多投资者对 UPS 决定到明年下半年将与 <strong>亚马逊</strong> 的业务量削减超过 50% 并不满意。有些人认为这一举动不明智，因为亚马逊是这家包裹递送公司的最大客户。</p>
<p>UPS 的管理团队疯了吗？我不这么认为。为亚马逊运输货物对 UPS 来说并不是一项特别有利可图的业务。逐渐减少与这家电子商务巨头的运输量，同时缩减资产和资源，应该会提高 UPS 的盈利能力，尽管收入下降。UPS 还将寻求通过扩大与其他（更有利可图的）客户的业务来抵消部分收入损失。</p>
<p>收入投资者仍然应该喜欢 UPS 的前瞻性股息收益率为 5.6%。该公司已经连续 16 年增加股息。尽管近年来的增幅较小，但 UPS 的股息似乎是安全的。</p>

霍顿房屋

联合包裹

<p>三只接近 52 周低点的股票被强调为潜在投资：1. D.R. Horton (DHI) 是美国最大的住宅建筑商，面临高抵押贷款利率的挑战，但长期前景良好，估值具有吸引力。2. 辉瑞 (PFE) 由于 COVID-19 产品销售下降而出现下滑，但拥有有前景的产品线和高股息收益率。3. 联合包裹 (UPS) 减少了与亚马逊的业务，但旨在通过专注于更有利可图的客户来提高盈利能力，同时保持稳健的股息收益率</p>

<p>Buy low, sell high. That has been a good strategy for investors for a long time. However, finding great stocks to buy under this approach might seem difficult right now, considering that the <strong>S&amp;P 500</strong> is close to its all-time high.</p>
<div class="lb-trans"><p>低买高卖。这一直是投资者长期以来的良好策略。然而，考虑到 <strong>标准普尔 500 指数</strong> 接近历史最高点，按照这种方法找到值得购买的优质股票可能看起来很困难。</p>
</div><p>The good news is that doing so is easier than you might think. Here are three magnificent stocks to buy that are near their 52-week lows.</p>
<div class="lb-trans"><p>好消息是，这样做比你想象的要容易。以下是三只接近 52 周低点的优秀股票。</p>
</div><h2>1. D.R. Horton</h2>
<div class="lb-trans"><h2>1. D.R. Horton</h2>
</div><p><strong>D.R. Horton</strong>(DHI 0.95%), the largest U.S. homebuilder by volume, has taken investors on a roller-coaster ride over the last 12 months. The ride hasn't been much fun lately, though, with the stock down more than 30% from the peak it set in September and barely above its 52-week low.</p>
<div class="lb-trans"><p><strong>D.R. Horton</strong>(DHI 0.95%)，美国最大的住宅建筑商，在过去 12 个月里让投资者经历了一场过山车般的旅程。不过，最近的旅程并不愉快，股票价格比 9 月份的峰值下跌了超过 30%，仅略高于其 52 周低点。</p>
</div><p>The main problem for D.R. Horton can be summed up in two words: mortgage rates. They remain stubbornly high despite the Federal Reserve's cuts to its benchmark interest rate late last year. When mortgage rates are high, fewer Americans can afford to buy new homes.</p>
<div class="lb-trans"><p>D.R. Horton 面临的主要问题可以用两个词来概括：抵押贷款利率。尽管美联储去年底降低了基准利率，但抵押贷款利率依然顽固地高企。当抵押贷款利率高时，越来越少的美国人能够负担得起购买新房。</p>
</div><p>Will mortgage rates decline soon? I don't know. What I do know, though, is that the long-term prospects for the U.S. housing market remain strong -- and that bodes well for D.R. Horton over the next decade.</p>
<div class="lb-trans"><p>抵押贷款利率会很快下降吗？我不知道。不过我知道的是，美国房地产市场的长期前景依然强劲——这对 D.R. Horton 在未来十年是个好兆头。</p>
</div><p>I also know that D.R. Horton's valuation is attractive. Its shares trade at only 9.9 times expected forward earnings. Even a hint of positive news on mortgage rates could provide a nice catalyst for this beaten-down stock.</p>
<div class="lb-trans"><p>我还知道 D.R. Horton 的估值很有吸引力。其股票的预期前瞻性市盈率仅为 9.9 倍。即使是关于抵押贷款利率的积极消息也可能为这只被打压的股票提供一个良好的催化剂。</p>
</div><h2>2. Pfizer</h2>
<div class="lb-trans"><h2>2. Pfizer</h2>
</div><p><strong>Pfizer</strong>(PFE -0.43%) stock has been on a generally downward trajectory since late 2021. That timing not-so-coincidentally roughly matches when the world was close to turning the corner on the COVID-19 pandemic. As sales for Pfizer's COVID-19 vaccines and antivirals sank, so did its share price. The big pharma stock is now near its lowest level of the last 52 weeks.</p>
<div class="lb-trans"><p><strong>Pfizer</strong>(PFE -0.43%) 的股票自 2021 年底以来一直处于普遍下滑的轨道。这一时机与全球接近走出 COVID-19 疫情的时刻不谋而合。随着 Pfizer 的 COVID-19 疫苗和抗病毒药物销售下滑，其股价也随之下跌。这只大型制药公司的股票现在接近过去 52 周的最低水平。</p>
</div><p>To be sure, Pfizer still faces some challenges. In particular, several of its products will lose patent exclusivity over the next few years, among them blockbuster drugs Eliquis, Ibrance, and Xtandi. The chances of COVID-19 vaccine sales returning to anywhere close to their peak levels are also slim to none.</p>
<div class="lb-trans"><p>当然，Pfizer 仍面临一些挑战。特别是，未来几年内其几款产品将失去专利独占权，其中包括重磅药物 Eliquis、Ibrance 和 Xtandi。COVID-19 疫苗销售回到接近峰值水平的机会也微乎其微。</p>
</div><p>However, Pfizer believes it will be able to deliver solid growth in the second half of this decade. How? The company's product lineup features rising stars such as migraine therapy Nurtec ODT and cancer drugs Padcev, Adcetris, and Tukysa. Pfizer's pipeline also includes 115 candidates, five of which are awaiting regulatory approvals and 32 that are in late-stage clinical testing.</p>
<div class="lb-trans"><p>然而，Pfizer 相信它将在本十年的下半年实现稳健增长。怎么做到的？该公司的产品线中有一些新兴明星，如偏头痛治疗药物 Nurtec ODT 和癌症药物 Padcev、Adcetris 和 Tukysa。Pfizer 的研发管线中还有 115 个候选药物，其中五个正在等待监管批准，32 个处于后期临床测试阶段。</p>
</div><p>Meanwhile, Pfizer stock is cheap, with a forward earnings multiple of only 8.7. The drugmaker also pays a dividend with a juicy forward yield north of 6.7% at the current share price.</p>
<div class="lb-trans"><p>与此同时，Pfizer 的股票便宜，前瞻性市盈率仅为 8.7 倍。这家制药公司还支付股息，目前股价的前瞻性收益率超过 6.7%。</p>
</div><h2>3. United Parcel Service</h2>
<div class="lb-trans"><h2>3. 联合包裹</h2>
</div><p>Shares of <strong>United Parcel Service</strong>(UPS 0.50%) have plunged by roughly 20% over the last 12 months. Despite a small bounce in recent days, the stock remains within striking distance of its 52-week low.</p>
<div class="lb-trans"><p><strong>联合包裹</strong>(UPS 0.50%) 的股票在过去 12 个月中暴跌了约 20%。尽管最近几天小幅反弹，但该股票仍然接近其 52 周低点。</p>
</div><p>Many investors weren't happy with UPS' decision to slash the volume of business it does with <strong>Amazon</strong> by more than 50% by the second half of next year. Some thought this move was ill-advised, considering that Amazon is the package delivery company's largest customer.</p>
<div class="lb-trans"><p>许多投资者对 UPS 决定到明年下半年将与 <strong>亚马逊</strong> 的业务量削减超过 50% 并不满意。有些人认为这一举动不明智，因为亚马逊是这家包裹递送公司的最大客户。</p>
</div><p>Is UPS' management team crazy? I don't think so. Moving goods for Amazon isn't an especially profitable business for UPS. Gradually decreasing shipment volumes for the e-commerce giant while simultaneously scaling back assets and resources should boost UPS' profitability despite the lower revenue. UPS will also seek to offset some of that revenue loss by expanding its business with other (more profitable) customers.</p>
<div class="lb-trans"><p>UPS 的管理团队疯了吗？我不这么认为。为亚马逊运输货物对 UPS 来说并不是一项特别有利可图的业务。逐渐减少与这家电子商务巨头的运输量，同时缩减资产和资源，应该会提高 UPS 的盈利能力，尽管收入下降。UPS 还将寻求通过扩大与其他（更有利可图的）客户的业务来抵消部分收入损失。</p>
</div><p>Income investors should still love UPS' forward dividend yield of 5.6%. The company has increased its payouts for 16 consecutive years. Although the hikes in recent years have been small, UPS' dividend appears to be safe.</p>
<div class="lb-trans"><p>收入投资者仍然应该喜欢 UPS 的前瞻性股息收益率为 5.6%。该公司已经连续 16 年增加股息。尽管近年来的增幅较小，但 UPS 的股息似乎是安全的。</p>
</div>

3 Magnificent Stocks to Buy That Are Near 52-Week Lows

- 当前市场接近历史高点，寻找低价股票变得困难。  
- D.R. Horton、Pfizer 和 United Parcel Service 是接近 52 周低点的优质股票。  
- 这些公司在各自领域面临挑战，但长期前景仍然看好。

3 只接近 52 周低点的绝佳股票值得购买